Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Clinical trial NCT06654050 · WITHDRAWN

Trial details

NCT number: NCT06654050
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Mesothelioma Malignant Mesothelioma (MM)Early-stage Mesothelioma Subclinical Mesothelioma BRCA1-Associated Protein-1 (BAP1) Mutations Early-stage BAP1-associated Malignancies

Start date: 2026-03-16
Primary completion: 2026-03-16
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.